Overview

S-Acetyl Glutathione (SAG) is a derivative of glutathione in which an acetyl group is attached to the sulfur atom of the cysteine residue within the glutathione tripeptide (gamma-glutamyl-cysteinyl-glycine). This acetylation was designed to address the fundamental bioavailability challenge of oral glutathione supplementation: native reduced glutathione (GSH) is rapidly degraded by gamma-glutamyltranspeptidase and dipeptidases in the gastrointestinal tract and liver, with studies showing that oral GSH produces minimal increases in circulating glutathione levels. The acetyl group shields the reactive thiol (-SH) group from oxidation and enzymatic degradation during transit through the digestive system, allowing the intact molecule to be absorbed into the bloodstream. Once inside cells, intracellular thioesterases (deacetylases) cleave the acetyl group, regenerating biologically active reduced glutathione.

Glutathione itself is the body's most abundant endogenous antioxidant, present at millimolar concentrations in virtually all cells. It serves as the primary intracellular redox buffer, a critical cofactor for glutathione peroxidases and glutathione S-transferases (Phase II detoxification enzymes), a recycler of other antioxidants including vitamin C and vitamin E, and a key player in immune cell function, mitochondrial protection, and heavy metal chelation. Glutathione depletion is implicated in aging, neurodegeneration, liver disease, pulmonary conditions, and impaired immune function. By providing a bioavailable oral form, SAG aims to replenish intracellular glutathione pools more effectively than standard glutathione supplements, with preliminary evidence suggesting it increases both plasma and intracellular glutathione levels.

SAG is typically dosed at 100-300 mg/day, taken on an empty stomach to minimize interference with other dietary proteins. While clinical data specifically on SAG is more limited than for liposomal glutathione or intravenous glutathione, the acetylation strategy has strong biochemical rationale and is supported by cell culture studies showing effective intracellular glutathione elevation. SAG also demonstrates direct antioxidant activity in its acetylated form before deacetylation, providing an additional layer of protection. It works synergistically with glutathione precursors such as NAC (N-acetyl cysteine, which provides cysteine substrate), alpha-lipoic acid (which recycles glutathione from its oxidized form), and selenium (a cofactor for glutathione peroxidase). For comprehensive glutathione support, combining SAG with precursor strategies offers both direct supplementation and enhanced endogenous production.

Mechanism of Action

S-Acetyl Glutathione (SAG) is a derivative of the tripeptide glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) in which an acetyl group is attached to the sulfhydryl group of the cysteine residue. This acetylation confers two critical pharmacokinetic advantages: protection from enzymatic degradation by gamma-glutamyltranspeptidase and dipeptidases in the gastrointestinal tract, and enhanced lipophilicity enabling direct passage across cell membranes without the need for carrier-mediated transport. Once inside cells, intracellular thioesterases remove the acetyl group, liberating free reduced glutathione (GSH).

The released GSH participates in the glutathione system, the body's primary endogenous antioxidant defense. GSH directly neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS) through its sulfhydryl group. It serves as the essential electron donor for glutathione peroxidase (GPx), which reduces hydrogen peroxide and lipid hydroperoxides to water and corresponding alcohols. The resulting oxidized glutathione (GSSG) is recycled back to GSH by glutathione reductase using NADPH, maintaining the cellular GSH/GSSG ratio critical for redox homeostasis.

In phase II detoxification, GSH conjugates with electrophilic xenobiotics and endogenous toxins via glutathione S-transferase (GST) enzymes, forming mercapturic acid conjugates that are excreted renally. GSH also chelates heavy metals (mercury, lead, arsenic) and participates in the regeneration of other antioxidants, notably vitamins C and E, through redox cycling. By maintaining adequate intracellular GSH levels, S-Acetyl Glutathione supports mitochondrial function, DNA repair processes, immune cell proliferation, and protein thiol maintenance.

Research

Safety Profile

Safety Profile: S-Acetyl Glutathione

Common Side Effects

• Mild gastrointestinal symptoms: nausea, bloating, and abdominal discomfort
• Headache during initial supplementation
• Mild sulfurous taste or breath
• Occasional skin rash or flushing

Serious Adverse Effects

• Very limited clinical trial data on this specific acetylated form
• Theoretical zinc and copper depletion with chronic high-dose use (glutathione chelates certain minerals)
• Possible interference with chemotherapy efficacy (antioxidant-based cancer treatment interaction)
• No confirmed reports of serious organ toxicity at standard doses (100–300 mg/day)

Contraindications

• Known hypersensitivity to glutathione or related thiol compounds
• Active cancer treatment with oxidative-stress-dependent chemotherapeutic agents (consult oncologist)
• Asthma (inhaled glutathione has triggered bronchospasm; oral form likely safe but caution warranted)

Drug Interactions

• Chemotherapy agents (cisplatin, doxorubicin): May reduce efficacy of agents that rely on oxidative damage to kill cancer cells
• Nitroglycerin: Glutathione may enhance nitrate tolerance
• Acetaminophen: Glutathione is protective against acetaminophen hepatotoxicity; supplementation may be beneficial
• Mineral supplements (zinc, copper): Possible chelation at high doses

Population-Specific Considerations

• Bioavailability advantage: S-acetyl form is designed to survive GI digestion better than reduced glutathione; however, head-to-head clinical comparisons are limited
• Liver disease patients: Glutathione depletion is common; supplementation may be beneficial under medical supervision
• Pregnancy/lactation: Insufficient safety data for supplemental doses
• Elderly: May benefit from age-related glutathione decline, but optimal dosing not established

Pharmacokinetic Profile